Published in Circ Res on January 02, 2015
Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Diet-Induced Arterial Stiffening in Female Mice. Hypertension (2015) 0.97
Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis. BMC Cardiovasc Disord (2016) 0.75
Mineralocorticoid receptor deficiency in macrophages inhibits atherosclerosis by affecting foam cell formation and efferocytosis. J Biol Chem (2016) 0.75
Mineralocorticoid receptor is involved in the aldosterone pathway in human red blood cells. Am J Transl Res (2016) 0.75
Global cardiovascular protection in chronic kidney disease. Nat Rev Cardiol (2016) 0.75
Rapid and MR-Independent IK1 Activation by Aldosterone during Ischemia-Reperfusion. PLoS One (2015) 0.75
Renin Angiotensin Aldosterone Inhibition in the Treatment of Cardiovascular Disease. Pharmacol Res (2017) 0.75
Primary aldosteronism: a common cause of resistant hypertension. CMAJ (2017) 0.75
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med (2004) 4.92
Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med (1955) 4.35
Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol (2006) 2.92
Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res (2005) 2.79
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation (2011) 2.71
Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med (2012) 2.59
Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension (2011) 2.51
Effects of aldosterone on the vasculature. Hypertension (2006) 2.32
Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension (2005) 2.29
[Constitution of aldosterone, a new mineralocorticoid]. Experientia (1954) 2.28
Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet (1952) 2.05
T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension (2011) 2.03
Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev (2003) 1.97
Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation (2000) 1.93
Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J (2011) 1.93
11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev (1997) 1.91
The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal (2007) 1.89
Specific, nongenomic actions of steroid hormones. Annu Rev Physiol (1997) 1.84
High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation (2006) 1.82
Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension (2002) 1.81
[Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism]. Experientia (1953) 1.80
The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm (2007) 1.76
The effect of adrenal extract on mineral metabolism. Lancet (1952) 1.75
50th anniversary of aldosterone. J Clin Endocrinol Metab (2003) 1.70
Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology (2004) 1.65
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail (2012) 1.62
Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension (2013) 1.59
Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis (2003) 1.59
Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation (2004) 1.57
Human arterial hypertension: a state of mild chronic hyperaldosteronism? Science (1956) 1.54
Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt. Arterioscler Thromb Vasc Biol (2013) 1.53
A radioimmunoassay for plasma aldosterone. J Clin Endocrinol Metab (1970) 1.51
Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens (2006) 1.48
Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology (2002) 1.45
Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens (2007) 1.44
T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension (2011) 1.35
Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol (2010) 1.35
A quantitative method for the bioassay of the effect of adrenal cortical steroids on mineral metabolism. Endocrinology (1952) 1.32
Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation (2004) 1.32
Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res (2009) 1.17
Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest (2010) 1.17
Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest (1983) 1.16
Secretion of aldosterone by the zona glomerulosa of rat adrenal glands incubated in vitro. Proc Soc Exp Biol Med (1956) 1.15
Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation (2005) 1.15
Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells. Circ Res (1995) 1.11
Rapid nongenomic aldosterone effects in the human forearm? Hypertension (2004) 1.11
Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension (2008) 1.10
Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol (2003) 1.07
Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol (1997) 1.07
Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int (2000) 1.05
Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther (1973) 1.05
Vascular actions of aldosterone. J Vasc Res (2012) 1.04
Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. J Am Heart Assoc (2013) 1.02
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail (2010) 1.02
[Synthesis in aldosterone-series. I. Total synthesis of racemic aldosterone]. Experientia (1955) 1.01
Primary aldosteronism: a new clinical entity. Trans Assoc Am Physicians (1955) 1.01
Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids (2011) 1.00
Mineralocorticoids, glucocorticoids, receptors and response elements. Science (1993) 0.99
Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension (2004) 0.99
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol (2006) 0.98
Aldosterone action. Annu Rev Physiol (1993) 0.97
Aldosterone and myocardial fibrosis in heart failure. Herz (2000) 0.97
Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens (2002) 0.96
Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens (2002) 0.95
Dual opposing roles of adaptive immunity in hypertension. Eur Heart J (2014) 0.95
Production of aldosterone by rat adrenal glands in vitro. Proc Soc Exp Biol Med (1957) 0.92
Subcellular localization of angiotensin II in kidney and adrenal. J Hypertens (2001) 0.92
Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br J Pharmacol (2013) 0.92
Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications. Curr Atheroscler Rep (2013) 0.90
Non-modulation as an intermediate phenotype in essential hypertension. Hypertension (1992) 0.89
Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens (2009) 0.87
The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function. Mol Cell Endocrinol (2004) 0.84
Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci U S A (2009) 0.84
Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol (1985) 0.84
Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am J Physiol Renal Physiol (2011) 0.84
Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovasc Res (2008) 0.84
Short term cardiovascular effects of aldosterone in healthy male volunteers. J Clin Endocrinol Metab (1999) 0.83
Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol (1984) 0.83
Aldosterone and PAI-1: implications for renal injury. J Nephrol (2002) 0.83
Isolation of crystalline aldosterone from the urine of patients with congestive heart failure. Experientia (1956) 0.82
Non-genomic aldosterone action: from the cell membrane to human physiology. J Steroid Biochem Mol Biol (2002) 0.82
11 beta-Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Pediatr Res (1997) 0.82
Aldosterone's rapid, nongenomic effects are mediated by striatin: a modulator of aldosterone's effect on estrogen action. Endocrinology (2014) 0.82
Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications. Clin Cardiol (2012) 0.81
Effects of aldosterone on Cx43 gap junction expression in neonatal rat cultured cardiomyocytes. Circ J (2009) 0.81
The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. Am J Med Sci (2002) 0.81
Rapid effects of aldosterone on vascular cells: clinical implications. Steroids (2004) 0.81
Abnormal renal sodium handling in essential hypertension. Relation to failure of renal and adrenal modulation of responses to angiotensin II. Am J Med (1986) 0.81
Angiotensin II AT1 receptor blockade normalizes CD11b+ monocyte production in bone marrow of hypercholesterolemic monkeys. Atherosclerosis (2007) 0.80
Immune modulation of resistance artery remodelling. Basic Clin Pharmacol Toxicol (2011) 0.80
Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. Int J Cardiol (2011) 0.79
Adrenal angiotensin: origin and site of generation. Am J Hypertens (2005) 0.78
Proarrhythmic effects of aldosterone during myocardial ischemia-reperfusion: implication of the sarcolemmal-KATP channels. J Cardiovasc Pharmacol (2014) 0.77
Vascular effects of aldosterone: sorting out the receptors and the ligands. Clin Exp Pharmacol Physiol (2013) 0.77